News

A poster session and ACMS keynote speaker Anant Madabhushi, MS, PhD, both delve into the use of AI in Mohs surgery.

Bar will share insight on foldover interpolated flaps for full thickness of nasal defects.

The ACMS president and scientific program chair share opportunities to discover innovations in Mohs surgery during this weekend’s meeting.

If you are attending the 2023 ACMS Meeting, check out these local attractions to soak up the best of Seattle between sessions.

May is National Skin Cancer and Melanoma Awareness Month. We have skin cancer at the forefront of our coverage this month. Here is a recap of the latest news about skin cancer research, studies, and more.

Experts in the field share why they enjoyed the 5th Annual Revolutionizing Atopic Dermatitis Conference and why it is unique.

Catch up on all coverage from Revolutionizing Atopic Dermatitis.

A single-site study involving an adult cohort with atopic dermatitis saw significant itch improvement.

Alexis discusses his Revolutionizing Atopic Dermatitis session, “Disparities in the Care of Atopic Dermatitis in the United States.”

Click here to answer this week's poll.

New data from RAD 2023 revealed the results of assessing the independent and combined effects of itch and skin severity on patient-reported symptoms and QoL.

The intention is to expedite the development and review of the drug helping adults with generalized pustular psoriasis.

The study examined the impact of an educational intervention on the population with the highest prevalence of the disease.

The drug was both safe and effective in patients ages 6 months to 5 years.

Candrice Heath, MD, FAAP, FAAD, reviewed the important conversations dermatologists need to have to understand how racism affects SOC patients with atopic dermatitis at RAD 2023.

Catch up on coverage from the third day of Revolutionizing Atopic Dermatitis.

Researchers determined there were no unique safety concerns in the study, which spanned 1000 patient years.

Jonathan Silverberg, MD, PhD, MPH, presented late-breaking dupilumab data at RAD 2023.

Gooderham’s sessions covered upcoming AD drug approvals, patient satisfaction and QoL improvement, and RAD 2023 takeaways.

Discussing photoprotection with patients is crucial as “Melanoma May" kicks off this month.

In a cohort of Chinese and Japanese pediatric patients, researchers deemed the topical treatment both safe and effective.

Raj Chovatiya, MD, PhD, discusses highlights from his sessions at RAD 2023 on best practices for AD management.

In 3 phase 3 clinical trials, the drug demonstrated significant improvements of AD when compared to a placebo.

Brett King, MD, PhD, gave an in-depth overview of how JAK inhibitors earned a boxed warning and what it means for treating patients with atopic dermatitis at RAD 2023.

In a diverse, urban cohort, researchers did not find discrepancies between disease severity or prescribed treatment.

De Benedetto shares her expertise on new discoveries in the science of atopic dermatitis at RAD 2023.

Catch up on coverage from the second day of Revolutionizing Atopic Dermatitis.

Bunick provides an overview of the most important highlights from his late-breaking session at RAD 2023.

Jonathan Silverberg, MD, PhD, MPH, shares highlights and key takeaways from his RAD 2023 sessions.